Showing results for

Search instead for

hrphow-faqs.docx

https://www.pharmac.govt.nz/assets/hrphow-faqs.pdf

Frequently Asked Questions 1. How do I/We become a HRPHOW wānanga host? Email Te Tira Whakarata Māori at PHARMAC, tewhaioranga@pharmac.govt.nz to let them know that you are interested in hosting a one day wānanga. 2. What level of funding does PHARMAC provide for a one day wānanga? To support the lo...

hauora-arotahi-summary-report-2018.docx

https://www.pharmac.govt.nz/assets/hauora-arotahi-summary-report-2018.pdf

SUMMARY OF THE HAUORA AROTAHI COMMUNITY CONSULTATION REPORT PREPARED FOR PHARMAC JUNE 2018 2 CONTENTS EXECUTIVE SUMMARY – HAUORA AROTAHI CONSULTATION 2018 ...............................................5 INTRODUCTION.......................................................................................

operating-policies-and-procedures-4th-ed.pdf

https://www.pharmac.govt.nz/assets/operating-policies-and-procedures-4th-ed.pdf

OPERATING POLICIES AND PROCEDURES OF PHARMAC (THE PHARMACEUTICAL MANAGEMENT AGENCY) Fourth Edition 27 January 2017 1 Contents 1. PHARMAC ................................................................................................................................. 3 1.1 Our objective and functions...

hiwinui-heke-scholarship-application.pdf

https://www.pharmac.govt.nz/assets/hiwinui-heke-scholarship-application.pdf

Hiwinui Heke Māori Pharmacy Student Scholarship Application Form In partnership with Ngā Kaitiaki o Te Puna Rongoā o Aotearoa, the Māori Pharmacists’ Association Inc (MPA), and PHARMAC this scholarship was established to support the education of Māori pharmacy students studying toward their Bachelor...

pacific-responsiveness-strategy-2017-2026.pdf

https://www.pharmac.govt.nz/assets/pacific-responsiveness-strategy-2017-2026.pdf

PHARMAC’S PACIFIC RESPONSIVENESS STRATEGY 2017-2026 KIA ORANA FAKAALOFA LAHI ATU TALOFA NI KAM NA MAURI MALO E LELEI HALO OLAKETA TALOFA NI SA BULA VINAKA MALO LAVA LE SOIFUA 3 Pacific Responsiveness Strategy STRATEGY FOREWORD STEFFAN CRAUSAZ - CHIEF EXECUTIVE Talofa, Kia orana, Ni sa bula vinaka, M...

TAR - Left atrial appendage occlusion devices

https://www.pharmac.govt.nz/tools-resources/research/tars/tar-left-atrial-appendage-occlusion-devices/

TAR - Left atrial appendage occlusion devices PHARMAC health economic assessment of left atrial appendage occlusion devices (LAAO) PHARMAC has been taking a greater role in the management of medical devices. PHARMAC is expected at some point in the future to take a role in assessing and managing acc...

How the Factors for Consideration affect Named Patient Pharmaceutical Assessment (NPPA)

https://www.pharmac.govt.nz/tools-resources/forms/exceptional-circumstances/nppa-with-factors/

How the Factors for Consideration affect Named Patient Pharmaceutical Assessment (NPPA) Who can make a NPPA application? Only authorised prescribers may submit NPPA applications, within their scope of practice. Only District Health Board (DHB) clinicians may submit Rapid Assessment NPPA applications...

Ethinyloestradiol 30 mcg with desogestrel 150 mcg (Marvelon): Discontinuation

https://www.pharmac.govt.nz/information-for/enquiries/oral-contraceptives-supply-updates/ethinyloestradiol-30-mcg-with-d...

Ethinyloestradiol 30 mcg with desogestrel 150 mcg (Marvelon): Discontinuation Marvelon is a combined oral contraceptive. The supplier – Merck Sharp & Dohme (MSD) – have discontinued the supply of this contraceptive. We understand that stock for Marvelon is currently depleted and there will be no fur...

Levonorgestrel 30mcg (Microlut): Supply issue

https://www.pharmac.govt.nz/information-for/enquiries/oral-contraceptives-supply-updates/levonorgestrel-30mcg-microlut/

Levonorgestrel 30mcg (Microlut): Supply issue Levonorgestrel 30 mcg (Microlut) is a progestogen-only contraceptive. The supplier, Bayer New Zealand Ltd, has advised there are currently shortages of Microlut.  PHARMAC has listed an alternative levonorgestrel tab 30 mcg product (also called Microlut) ...

Named Patient Pharmaceutical Assessment (NPPA) decisions

https://www.pharmac.govt.nz/tools-resources/forms/exceptional-circumstances/nppa-decisions/

Named Patient Pharmaceutical Assessment (NPPA) decisions 1 March 2012 to 31 August 2017 This is a list of decisions on NPPA applications – both approvals and declines. We’ve withheld some decisions to maintain patient confidentiality. Approximately 1/3 of all submitted applications didn’t met the un...

Cilazapril brand change

https://www.pharmac.govt.nz/medicines/my-medicine-has-changed/cilazapril/cilazapril-brand-change/

Cilazapril brand change Cilazapril is used to treat a number of conditions including high blood pressure, heart failure and diabetic kidney disease. It is also used in people who have previously had a heart attack. What changed? The funded brand of cilazapril changed from Apo-Cilazapril to the Zapri...

Lamotrigine Review: The Sole Supply Decision – The decision making process

https://www.pharmac.govt.nz/medicines/my-medicine-has-changed/lamotrigine-epilepsy-drug-changes/independent-review-of-ph...

Lamotrigine Review: The Sole Supply Decision – The decision making process The Sole Supply Decision was made by PHARMAC’s Board at its meeting on 29 March 2019. The documentation before the Board demonstrates that the March 2019 decision was the culmination of a decision making process that could be...

Lamotrigine Review: Decision making by PHARMAC – General approach and principles

https://www.pharmac.govt.nz/medicines/my-medicine-has-changed/lamotrigine-epilepsy-drug-changes/independent-review-of-ph...

Lamotrigine Review: Decision making by PHARMAC – General approach and principles Before considering the Sole Supply Decision, it is useful to summarise PHARMAC’s general approach to making decisions about the funding of medicines. This is not intended as an exhaustive summary of either PHARMAC’s pro...

Lamotrigine Review: Appendix 2 – Associate Professor Doogue’s advice

https://www.pharmac.govt.nz/medicines/my-medicine-has-changed/lamotrigine-epilepsy-drug-changes/independent-review-of-ph...

Lamotrigine Review: Appendix 2 – Associate Professor Doogue’s advice From: A/Prof Matthew Doogue  Department of Medicine  University of Otago Christchurch To: Dr Jonathan Coates Claro 19 April 2020 Re: Independent Review of PHARMAC’s Lamotrigine Sole Supply Decision I am a qualified medical practiti...

Lamotrigine review: Appendix 1 – Terms of Reference

https://www.pharmac.govt.nz/medicines/my-medicine-has-changed/lamotrigine-epilepsy-drug-changes/independent-review-of-ph...

Lamotrigine review: Appendix 1 – Terms of Reference Terms of Reference for the Independent Review of PHARMAC’s Lamotrigine Sole Supply Decision Background: On 11 April 2019 PHARMAC decided to award sole supply of the drug lamotrigine to a single brand, Logem, supplied by Mylan (the “sole supply deci...

Lamotrigine review | 1.0 Introduction

https://www.pharmac.govt.nz/medicines/my-medicine-has-changed/lamotrigine-epilepsy-drug-changes/independent-review-of-ph...

Lamotrigine review | 1.0 Introduction The Pharmaceutical Management Agency (PHARMAC) is the crown entity responsible for deciding which medicines and medical devices are publicly funded in New Zealand. PHARMAC’s objectives include securing the best health outcomes that are reasonably achievable from...

Prescribing medicines restricted in the HML

https://www.pharmac.govt.nz/tools-resources/pharmaceutical-schedule/hml-online-section-h/prescribing-restricted-medicine...

Prescribing medicines restricted in the HML Some medicines in Section H (HML) have prescriber-type or indication restrictions. Prescribing a medicine on the HML This flow chart shows the steps to take if there are restrictions on a medicine. Flow chart description: Start: I want to prescribe a pharm...

Rongoā medicine

https://www.pharmac.govt.nz/maori/he-rongoa-pai/rongoa-medicine/

Rongoā medicine E hoa mā! Inā te ora o te tangata. O friends! Here indeed is the health of mankind.   Ngā Pēpeha a ngā Tīpuna, The Sayings of the Ancestors, Nā Hirini Moko Mead rāua ko Neil Grove, Victoria University Press (2001). New Zealand has a long history of rongoā Māori (traditional healing) ...

Cilazapril with hydrochlorothiazide: Discontinuation

https://www.pharmac.govt.nz/medicines/my-medicine-has-changed/cilazapril/discontinuation-of-cilazapril-with-hydrochlorot...

Cilazapril with hydrochlorothiazide: Discontinuation Cilazapril with hydrochlorothiazide is a medicine used for the treatment of patients with hypertension who are not adequately controlled on monotherapy. This medicine may also be used for other indications. What's changing? Apotex, the supplier of...

Filgrastim change

https://www.pharmac.govt.nz/medicines/new-medicines/medicine-pricing/biosimilar-filgrastim-2/filgrastim-sidebar-2/

Filgrastim change A view from the front line Increased use of GCSFs (filgrastim and pegfilgrastim) has led to significantly improved health outcomes for cancer patients. That’s the finding of clinicians from MidCentral Regional Cancer Treatment Services, reported at the NZ Society for Oncology 2014 ...